Antimicrobial resistance is a major emerging threat as reported by the WHO1. Worldwide implementation of bacteriophage therapy, a 100-year old treatment employing the natural enemies of bacteria, is impeded by the lack of common manufacturing procedures which meet international quality and safety standards2. Based on synthetic biology we created a cell-free molecular assembly line for bacteriophages. We demonstrate expression of several phages including T7, MS2 and GEC-3S at clinically relevant concentrations. Exploiting the open nature of cell-free systems, this platform enables modular composition of bacteriophages with engineered proteins while remaining GMO-free. We developed a quality control structure utilizing state-of-the-art bioinformatics, as well as purification and encapsulation protocols. To expand our production variety while reducing cost, we optimized and engineered home-made E. Coli cell-extract. Compared to traditional manufacturing procedures, we require 2.5% of the production volume and demands no special biosafety regulations to yield bacteriophages ready for therapy.
Cell-Free Expression System
The molecular heart of our production pipeline is a cell-free expression system3. Screening over 50 parameters, we optimized a self-made chassis for assembly of bacteriophages. From a culture of the Rosetta2 (DE3) E. coli strain, cell extract is prepared by following improved cultivation and lysis protocols. Lyophilisation of the cell-free system paves the way for storage at room temperature and easy distribution.
Characterizing All Variables of a Cell-Free System
Manufacturing a pharmaceutical product requires fulfilment of the utmost standards. To ensure a constantly high-grade product, extensive quality control measures have been implemented. Expression capability of the cell-free system is assessed on the basis of a malachite green aptamer and an mTurquoise construct, enabling independent evaluation of transcription and translation, complemented by an overall protein content measurement.
Synthetic Phage Manufacturing
Purified linear DNA templates are assembled to functional bacteriophages. Creating independence from the living bacterial host, our cell-free system is capable of assembling any desired phage during a typical incubation time of four hours. Apart from combining the two components of our cell extract, phage assembly requires inhibition of the recombinase complex RecBCD by addition of purified GamS protein4. Incorporation of dNTPs increases phage yield by allowing DNA amplification throughout the reaction.
Quantification of DNA-Contamination Using Sequ-Into
To assess the quality of our phage DNA, we performed third generation sequencing using nanopore technology. A high DNA quality is especially critical for many therapeutic bacteriophages whose genome sequence is not known. In our initial sequencing attempts, we noticed that traditional purification methods for phage DNA retained large amounts of contamination from E. coli genomes. By sequencing different phage batches and determining the level of contamination, we could evaluate and enhance our purification protocols drastically, up to 96% purity5.
Assessing Phage Functionality
Receiving functional phages is crucial for curing patients. A special focus of Invitris rests upon monitoring of phage functionality. We implemented a plaque assay to ensure that the phages are capable of infecting and eliminating bacteria.
Our cell free production pipeline demands minimal purification efforts. We demonstrated absence of detectable immunogenic endotoxins in our modified cell extract preparation with the FDA-validated Limulus Amebocyte Lysate (LAL) test.
The final component of our production pipeline is a hardware-supported microencapsulation in monodisperse spheres consisting of an alginate and CaCO3 polymer. Protecting the phages against low pH and pepsin, our packaging approach allows gastric passage and intestinal delivery. In addition, the encapsulation enhances storage capabilities of the phage product.
- High levels of antibiotic resistance found worldwide, new data shows
- Phage Therapy in Clinical Practice: Treatment of Human Infections, Current Pharmaceutical Biotechnology (2010) 11: 69
- An E. coli Cell-Free Expression Toolbox: Application to Synthetic Gene Circuits and Artificial Cells
- The Protein GamS Inhibits RecBCD Binding to dsDNA Ends
- A window into third-generation sequencing
- Good Manufacturing Practice (GMP)
- Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers